Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP
Ping Fang,1 Zhengqin Ye,1 Ran Li,1 Dunmin She,2 Guannan Zong,1 Liya Zhang,1 Ying Xue,1 Keqin Zhang1 1Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, People's Republic of China; 2Department of Endocrinology, Northern Jiangsu P...
Saved in:
Main Authors: | Fang P (Author), Ye Z (Author), Li R (Author), She D (Author), Zong G (Author), Zhang L (Author), Xue Y (Author), Zhang K (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017) -
Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023) -
Transforming growth factor-beta and microRNA-21, microRNA-29b, microRNA-92, and microRNA-129 in systemic sclerosis patients: a case-control study
by: Mohammed Hassan Mohammed, et al.
Published: (2022) -
Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021) -
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
by: Laurie L. Baggio, et al.
Published: (2021)